Actelion FVE Continues to Reflect Stand-Alone Valuation as We Wait for Deal Confirmation
Rumors of an imminent acquisition have surrounded Actelion since November, but we're maintaining our fair value estimate of CHF 112 per share (based on our assessment of the stand-alone value of the firm) until we hear confirmation of a pending deal. News media report that both Johnson & Johnson and Sanofi failed to close a deal with Actelion in December, despite J&J offering roughly CHF 260 per share ($28 billion) and Sanofi roughly CHF 275 per share ($29 billion, including a contingent...
Morningstar, Inc. is a leading provider of independent investment research in North America, Europe, Australia, and Asia. The company offer an extensive line of products and services for individual investors, financial advisors, asset managers, and retirement plan providers and sponsors.
Morningstar provides data on approximately 530,000 investment offerings, including stocks, mutual funds, and similar vehicles, along with real-time global market data on more than 18 million equities, indexes, futures, options, commodities, and precious metals, in addition to foreign exchange and Treasury markets. Morningstar also offers investment management services through its investment advisory subsidiaries and had approximately $185 billion in assets under advisement and management as of June 30, 2016.
We have operations in 27 countries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.